Circio Holding ASA (CRNA) 4

[TekBot]

Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders

Oslo, 21 January 2026: Reference is made to the stock exchange announcements
by Circio Holding ASA (the “Company”) on 15 January 2026, regarding the
commencement of the subscription period for the rights issue (the "Rights
…

Vis børsmeldingen

Issue") and the receipt of subscription rights in the Rights Issue by certain
primary insiders and close associates.

Oslo, 21 January 2026: Reference is made to the stock exchange announcements
by Circio Holding ASA (the “Company”) on 15 January 2026, regarding the
commencement of the subscription period for the rights issue (the “Rights
Issue”) and the receipt of subscription rights in the Rights Issue by certain
primary insiders and close associates.

Certain primary insiders and close associates have on the dates as stated
below, exercised subscription rights and subscribed for shares:

• Ola Melin, Chief Operation Officer of the Company has on 21 January 2026
  exercised 33,161 subscription rights, thus entitling him to be allocated
  33,161 offer shares in the Rights Issue. In addition, Ola Melin has
  subscribed for 116,839 offer shares without subscription rights, thereby
  subscribing for a total of 150,000 offer shares at the subscription price in
  the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a
  corresponding number in warrants without additional consideration, subject
  to allocation by the board of directors and the completion of the Rights
  Issue.

• Thomas Birkballe Hansen, Chief Technology Officer of the Company has on 19
  January 2026 exercised 32,582 subscription rights, thus entitling him to be
  allocated 32,582 offer shares in the Rights Issue. In addition, Thomas
  Birkballe Hansen has subscribed for 167,418 offer shares without
  subscription rights, thereby subscribing for a total of 200,000 offer shares
  at the subscription price in the Rights Issue, i.e., NOK 1.00 per offer
  share, and to be allocated a corresponding number in warrants without
  additional consideration, subject to allocation by the board of directors
  and the completion of the Rights Issue.

• Diane Mary Mellet, Board member of the Company has on 21 January 2026
  exercised 60,000 subscription rights, thus entitling her to be allocated
  60,000 offer shares in the Rights Issue, at the subscription price in the
  Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a
  corresponding number in warrants without additional consideration, subject
  to the completion of the Rights Issue.

• Robert Forbes Burns, Deputy Board member of the Company has on 21 January
  2026 exercised 11,542 subscription rights, thus entitling him to be
  allocated 11,542 offer shares in the Rights Issue, at the subscription price
  in the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a
  corresponding number in warrants without additional consideration, subject
  to the completion of the Rights Issue.

• Damian Marron, Chairman of the Board of the Company has on 21 January 2026
  exercised 58,918 subscription rights, thus entitling him to be allocated
  58,918 offer shares in the Rights Issue. In addition, Damian Marron has
  subscribed for 61,082 offer shares without subscription rights, thereby
  subscribing for a total of 120,000 offer shares at the subscription price in
  the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a
  corresponding number in warrants without additional consideration, subject
  to allocation by the board of directors and the completion of the Rights
  Issue.

Please see the attached notifications of trade for information regarding the
subscription rights exercised by primary insiders in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

Kilde

[laban9]

Du vet at de tegningsrettene kan selges?

Hvis du ikke skal bruke de er det jo greit å få noen kroner for de.

[skeptiker]

Jeg visste de kunne selges, men tenkte kursen var klart lavere enn den viste seg å være. Ut fra siste kurs ser det ut til at jeg kan tjene ca 900 kr på å selge dem.

[Freddys]

Denne kom opp i Finansavisen, går det litt tregt med å få inn kr?

[Den.nye.vinen]

EW nevnte under intervjuet på Biostock.se at “kjærlighetsforholdet” med Big Pharma-selskapet som de nå samarbeider med startet i mars 2025. Det samsvarer godt med denne konferansen som de også selvsagt deltar på i år. Vi har vel ikke noe imot nye flørter, eller faste forhold for den del…?
March 18 - March 19, 2026
LSX RNA Leaders Europe
March 18 - March 19, 2026
Vienna, Austria

[zappa66]

Based on a platform-focused rNPV framework, we derive a present value of NOK 2.03 per share in a Base scenario.

Circio Holding - Analyst Group

In a Bull scenario, we estimate a more favorable commercial outcome for Circio driven by stronger-thanexpected preclinical validation of the circVec platform and accelerated partner interest. Specifically, we model three licensing agreements, reflecting broader adoption of circVec across multiple applications, two of which relate to AAV-circVec. These assume larger scope, higher upfront payments, and increased total deal values relative to the Base scenario, underpinned by stronger disease-relevant efficacy data and clearer translational relevance. More specifically, we assume upfront payments of USD 50m and USD 100m, respectively, and total deal values of USD 700m and USD 1,500m. Peak sales assumptions for the partnered programs are correspondingly higher, reflecting both improved competitive positioning and access to more commercially attractive indications. The larger and earlier upfront payments assumed in the Bull scenario are estimated to strengthen Circio’s funding position, enabling the Company to bridge to an initial licensing agreement without additional external financing.
In addition, we estimate a third licensing agreement in the Bull scenario within in vivo CAR therapies. While the in vivo CAR field remains preclinical across the industry, with no human efficacy data to date, we assume that positive early validation of circVec’s differentiated expression profile could enable Circio to enter a platform-level collaboration or licensing agreement. Given the early-stage nature of the field and circVec’s dependence on delivery technologies outside Circio’s control, this opportunity is modelled conservatively through a risk-adjusted upfront payment of approx. NOK 100m, with no explicit modelling of downstream milestones or product sales. This approach captures upside optionality while maintaining valuation discipline.

Moreover, in a Bull scenario, Circio may represent an attractive acquisition target, either as a platform bolton to enhance lifecycle management of existing gene therapies or as a longer-term strategic investment in next-generation gene expression technologies.
Based on a rNPV model, a WACC of 14%, and consideration of the current capital structure, a present market value of NOK 1,814m is derived, corresponding to NOK 7.45 per share in a Bull scenario

[Investor]

Aksjen 1.13,

T-rett 0.11.

Rart ikke folk hiver seg over t-retten nå. Gratis warrant.

[WernerVonHaussenberg]

@Investor

Rart ikke folk hiver seg over t-retten nå

Fordrer jo at du har lyst til å eie akjsen i utgangspunktet, da.

[He-man]

Hei,
Noen her som har sendt flere bestillinger (bestillingsskjemaer) for nye aksjer?

Jeg har også to kontoer (VP og ASK) og tenker å slenge inn en bestilling til hver, men ikke om den andre bestillingen kansellerer den første:)

[Xon]

Du kan sende 2 bestillinger.
Send deretter e-post til retail@dnb.no og informer.

[polygon]

Men det er noe alvorlig irrasjonelt nå når folk faktisk kjøper aksjen til 1,17 i stedet for å kjøpe TR til 0,12

…jeg har ingen aksjer lenger i hvert fall

[Boms]

Den arbitrasjen er jo en no-brainer, synd jeg også solgte aksjer og kjøpte tegningsretter for noen dager siden.

[aol]

Oppdaterte events

[He-man]

Bytta 1:1 aksjer 1,07 mot t-retter 0,2 forrige uke. Trodde det var en god deal.

I dag ble det 1,14 mot 0,12.

Blir spennende å se siste dag med handling av t-retter i morgen. Kanskje salget er over?

Håper ellers på overtegning i emisjonen med 0 på garantist og litt ekstra tildeling på meg😊

[Investor]

Hvor mye kan vi forvente å få i overtegning?

[tverilytt]

Trodde folk her var litt mer langsiktige, gidder ikke, og har ikke tid til, å drive med øretrilling. Men god omsetning er da enda noe

EDIT: Men det er toppen hvis folk kjøper TR, jo flere som tegner jo bedre for selskapet, honnør for det!

[TekBot]

Circio Holding ASA Last day of trading in subscription rights in the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA,
CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 23 January 2026: Reference is made to the stock exchange announcement by
Circio Holding ASA (the “Company”) on 15 January 2026, regarding the
commencement of the subscription period for the rights issue of up to NOK 50
million in the Company (the “Rights Issue”). NOK 44.2 million has been secured
through pre-subscriptions for NOK 24.2 million and underwriting commitment of
NOK 20 million.

The trading period in the Subscription Rights in the Rights Issue with ticker
“CRNAT” will expire today, on 23 January 2026 at 16:30 hours (CET).

Subscription Rights that are not sold before close of trading today, 23
January 2026 at 16:30 hours (CET) or not used to subscribe for offer shares
before the expiry of the subscription period on 29 January 2026 at 16:30 hours
(CET) will have no value and will lapse without compensation to the holder.

For the complete terms and conditions, including the Prospectus published in
relation to the Rights Issue and the subscription form for the Rights Issue,
please visit: https://www.circio.com/en/rightsissue2026/.

The prospectus comprising a registration document approved and published on 1
October 2025, a registration document supplement, a securities note and a
summary, approved and published on 13 January 2026 (jointly, the “Prospectus”)
is also found via this link https://www.circio.com/en/rightsissue2026/.

Subscription procedure:

• Norwegian residents with a Norwegian personal identification number who wish
  to subscribe for Offer Shares (incl. Offer Warrants) are encouraged to use
  the VPS online subscription system via the below link:
  *
  Bostedskontroll
• Legal entities and foreign residents must submit the subscription form in
  order to subscribe for offer shares.

---

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

– IMPORTANT INFORMATION –
This announcement is not and does not constitute an offer of securities for
sale or a solicitation of an offer to purchase securities of the Company in
the United States or any other jurisdiction. Copies of this document may not
be sent to jurisdictions, or distributed in or sent from jurisdictions, in
which this is barred or prohibited by law. The securities of the Company may
not be offered or sold in the United States absent registration or an
exemption from registration under the U.S. Securities Act of 1933, as amended
(the “U.S. Securities Act”).

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act.
No public offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made
by means of a prospectus (the “Prospectus”) which will be prepared and which
is subject to the approval by the Norwegian Financial Supervisory Authority.
This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of
14 June 2017 on prospectuses to be published when securities are offered to
the public or admitted to trading on a regulated market, and repealing
Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the
“Prospectus Regulation”). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained
in the Prospectus. Copies of the Prospectus will, following publication, be
available from the Company’s registered office and, subject to certain
exceptions, on the websites of the Managers.

In any EEA Member State other than Norway, this communication is only
addressed to and is only directed at qualified investors in that Member State
within the meaning of the Prospectus Regulation, i.e., only to investors who
can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as “Relevant Persons”). These materials are directed only at Relevant
Persons and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this announcement
relates is available only to Relevant Persons and will be engaged in only with
Relevant Persons. Persons distributing this communication must satisfy
themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Manager is acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to its clients or for providing advice in
relation to the Rights Issue or any transaction or arrangement referred to in
this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. This announcement is made by and is the responsibility of, the
Company. Neither the Manager nor any of its affiliates makes any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

Kilde

[Baerntis]

Ikke mye nytt her. Men en grei påminnelse om at circvec har en plass som et mulig missing link i dette spacet

Hacking Evolution: Reprogramming Viruses into Medicines - VIROLOGY RESEARCH...

Og når det gjelder feasibility som nå er kjent som AAV-brain/CNS - “AAV vectors are being investigated for neurodegenerative conditions including Parkinson’s and Alzheimer’s disease, with some improvement in motor symptoms reported.” - så kan det jo tenkes ? Dersom Roche. Studie i to armer; Dyno(capside)+circvec og Manifold(BBB)+circvec.

[WernerVonHaussenberg]

28/1 som er siste dag man kan veksle inn TR her?

[polygon]

Siste dag med handel i TR i dag. Siste frist for tegning er 29. januar 16.30